Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Rein Therapeutics Inc.
Rein Therapeutics Inc. News
Jan 9, 2026 - defenseworld.net
Rein Therapeutics (NASDAQ:RNTX) Shares Down 0.8% – Here’s Why
Nov 3, 2025 - benzinga.com
Why Is Rein Therapeutics Stock Trading Higher On Monday?
Oct 9, 2025 - globenewswire.com
Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
Sep 17, 2025 - globenewswire.com
Rein Therapeutics Announces Publication of New Translational Data in iScience on Company's Novel Therapy for Idiopathic Pulmonary Fibrosis
Rein Therapeutics Inc. Quantitative Score
About Rein Therapeutics Inc.
Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.
Rein Therapeutics Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Rein Therapeutics Inc. Financials
Table Compare
Compare RNTX metrics with: | |||
|---|---|---|---|
Earnings & Growth | RNTX | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | RNTX | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | RNTX | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | RNTX | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Rein Therapeutics Inc. Income
Rein Therapeutics Inc. Balance Sheet
Rein Therapeutics Inc. Cash Flow
Rein Therapeutics Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Buy |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Rein Therapeutics Inc. Executives
| Name | Role |
|---|---|
| James Brian Windsor | Chief Executive Officer, President & Director |
| Cory Hogaboam | Chief Scientific Officer |
| Ron Chen | Vice President of Finance and Corporate Controller |
| Timothy Cunningham | Interim Chief Financial Officer & Principal Accounting Officer |
| Jennifer Faigle | Counsel |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| James Brian Windsor | Chief Executive Officer, President & Director | 1966 | 753.42K | |
| Cory Hogaboam | Chief Scientific Officer | -- | ||
| Ron Chen | Vice President of Finance and Corporate Controller | Male | -- | |
| Timothy Cunningham | Interim Chief Financial Officer & Principal Accounting Officer | Male | 1962 | -- |
| Jennifer Faigle | Counsel | Female | -- |
Rein Therapeutics Inc. Insider Trades
| Date | 14 Nov |
| Name | Voss Capital, LP |
| Role | 10 percent owner |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 104183 |
| Date | 24 Oct |
| Name | Voss Capital, LP |
| Role | 10 percent owner |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 30176 |
| Date | 27 Oct |
| Name | Voss Capital, LP |
| Role | 10 percent owner |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 92642 |
| Date | 27 Oct |
| Name | Voss Capital, LP |
| Role | 10 percent owner |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 4840 |
| Date | 28 Oct |
| Name | Voss Capital, LP |
| Role | 10 percent owner |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 178392 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 14 Nov | Voss Capital, LP | 10 percent owner | Acquired | P-Purchase | 104183 |
| 24 Oct | Voss Capital, LP | 10 percent owner | Acquired | P-Purchase | 30176 |
| 27 Oct | Voss Capital, LP | 10 percent owner | Acquired | P-Purchase | 92642 |
| 27 Oct | Voss Capital, LP | 10 percent owner | Acquired | P-Purchase | 4840 |
| 28 Oct | Voss Capital, LP | 10 percent owner | Acquired | P-Purchase | 178392 |